Calithera Biosciences Stock Price To Earnings To Growth
| CALADelisted Stock | USD 0.05 0.00 0.00% |
Calithera Biosciences fundamentals help investors to digest information that contributes to Calithera Biosciences' financial success or failures. It also enables traders to predict the movement of Calithera Pink Sheet. The fundamental analysis module provides a way to measure Calithera Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Calithera Biosciences pink sheet.
Calithera |
Calithera Biosciences Company Price To Earnings To Growth Analysis
Calithera Biosciences' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Calithera Biosciences Price To Earnings To Growth | (0.29) X |
Most of Calithera Biosciences' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Calithera Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
CompetitionBased on the latest financial disclosure, Calithera Biosciences has a Price To Earnings To Growth of -0.29 times. This is 140.85% lower than that of the Biotechnology sector and 109.24% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 105.93% higher than that of the company.
Calithera Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Calithera Biosciences' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Calithera Biosciences could also be used in its relative valuation, which is a method of valuing Calithera Biosciences by comparing valuation metrics of similar companies.Calithera Biosciences is currently under evaluation in price to earnings to growth category among its peers.
Calithera Fundamentals
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.56 | ||||
| Current Valuation | (1.1 M) | ||||
| Shares Outstanding | 4.87 M | ||||
| Shares Owned By Insiders | 1.07 % | ||||
| Shares Owned By Institutions | 26.76 % | ||||
| Number Of Shares Shorted | 417.28 K | ||||
| Price To Earning | (14.08) X | ||||
| Price To Book | 1.86 X | ||||
| Price To Sales | 1.71 X | ||||
| Gross Profit | (42.7 M) | ||||
| EBITDA | (43.77 M) | ||||
| Net Income | (39.65 M) | ||||
| Cash And Equivalents | 41.79 M | ||||
| Cash Per Share | 8.59 X | ||||
| Total Debt | 1.67 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 4.82 X | ||||
| Book Value Per Share | (0.40) X | ||||
| Cash Flow From Operations | (43.61 M) | ||||
| Short Ratio | 0.78 X | ||||
| Earnings Per Share | (1.59) X | ||||
| Price To Earnings To Growth | (0.29) X | ||||
| Target Price | 5.0 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 341.07 K | ||||
| Total Asset | 28.68 M | ||||
| Retained Earnings | (512.62 M) | ||||
| Working Capital | 19.23 M | ||||
| Current Asset | 72.5 M | ||||
| Current Liabilities | 3.83 M | ||||
| Z Score | -29.14 | ||||
| Net Asset | 28.68 M |
About Calithera Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Calithera Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Calithera Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Calithera Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Calithera Pink Sheet
If you are still planning to invest in Calithera Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Calithera Biosciences' history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |